Taranabant is the generic name given to a new trial medication being tested for the fight against obesity.

With obesity being such a huge problem in society today, there is a large demand for medications fighting it. And currently there is a new medication in the works which has been given the generic name Taranabant. There is still no official trademarked name for which Merck will most certainly obtain. It is still in the trial stages of development/testing but apparently Merck will apply to the FDA sometime 2008. What does this mean? Well that there could be shortly a new medication to fight obesity available in the US. Earlier in 2007, Rimonabant was voted against being recommended for the US. Although there are many other countries using it now.

The main problem with Acomplia is that is not manufactured by a US laboratory such as Merck so we think because of this that Sanofi  has no chance to get brand Acomplia in the Us Market.

Acomplia works great.More and more people are satisfied with the results obtained with the generic version of Acomplia (Rimonabant).Its all about politics,even if Rimonabant works fine and is the first diet pill for long term usage its still not approved,we are talking about Big money here so FDA will wait for Merck

In the quest to become lean, the new weight loss medication Taranabant is being tested to determine if the benefits are qualified enough to be put on the market. Currently (Jan 2008) the latest phase of testing is proceeding.
The latest study (phase 3) so far indicates that Taranabant indeed does help people lose weight. The people taking taranabant as apposed to the people taking the placebo did lose the most weight, even at lower doses Taranabant is appearing to be working which is quit surprising and could be very
beneficial in getting it approved for the market.

Both rimonabant and taranabant have their differences but with similarities as well. They target the CB-1 receptors in the body’s Endocannabinoid System which takes on many important tasks including things like food intake/anxiety/fear etc. To the general population, they work to reduce ones weight and cravings for food. What remains to be seen is once the final trials are performed for taranabant just how the side effects differ from rimonabant. There is also the possibility that in time the FDA reviews rimonabant again and deems it to be acceptable for the US population as many other countries around the world have. Only time will tell but things are looking fairly positive currently for Taranabant, we will see what happens in 2008 if Merck goes before the FDA.